The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Does the addition of venetoclax to low-dose conditioning improve outcome after allo-HSCT?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Jacqueline Garcia, Dana-Farber Cancer Institute, Boston, US. We asked, Does the addition of venetoclax to low-dose conditioning improve outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT)?

Does the addition of venetoclax to low-dose conditioning improve outcome after allo-HSCT?

Garcia reports the results of the dose-escalation and expansion cohorts from a phase I study investigating the safety and efficacy of adding venetoclax to fludarabine and busulfan reduced intensity conditioning chemotherapy prior to allo-HSCT in patients with high-risk myeloid malignancies.

Share: